Panobinostat
Malignant Pericardial Effusion
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Malignant Pericardial Effusion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin National Cancer Institute (NCI) | Phase 2 | BB |
Recombinant Interleukin-12 National Cancer Institute (NCI) | Phase 1 | CC |
TRASTUZUMAB National Cancer Institute (NCI) | Phase 1 | CC |
Abi-007 National Cancer Institute (NCI) | Phase 1 | CC |
Rivoceranib Fox Chase Cancer Center | N/A | D |
LENVATINIB Fox Chase Cancer Center | N/A | D |
Sorafenib Fox Chase Cancer Center | N/A | D |
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →